# Study of Etanercept in the Treatment of Psoriasis in Adult Subjects

> **NCT00121615** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 391 (—)

## Conditions studied

- Inflammation
- Psoriasis

## Interventions

- **DRUG:** etanercept

## Key facts

- **NCT ID:** NCT00121615
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-10
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 391 (—)
- **Last updated:** 2009-03-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00121615

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00121615, "Study of Etanercept in the Treatment of Psoriasis in Adult Subjects". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT00121615. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*